Shopping Cart 0
Cart Subtotal
AED 0

Morphotek Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Morphotek Inc (Morphotek), a subsidiary of Eisai Inc, is a clinical-stage biotechnology company that develops monoclonal antibodies, antibody drug conjugates, and bispecific antibodies to treat cancer, inflammatory and infectious diseases. Its pipeline product portfolio includes farletuzumab, a humanized IgG1 antibody targeting folate receptor alpha (FRA) for the treatment of ovarian and lung cancers; and amatuximab, a chimeric, IgG1 antibody that targets a cell-surface glycoprotein, mesothelin for treating mesothelioma. Morphotek also provides ontuxizumab targets cell-surface protein, endosialin for the treatment of cancers; gimsilumab against rheumatoid arthritis (RA); MORAb-202, an antibody drug conjugate (ADC) for metastatic breast cancer; and MORAb-048, MORAb-050 and MORAb-066 targeting tissue factor (TF) expressing malignancies. It offers services such as drug discovery and development, GLP and GMP production, antibodies investigation, antibody and protein engineering technologies, and others. The company works in partnership with other biotech companies, research organizations, and academic centers for discovery and development of its pipeline products. Morphotek is headquartered in Exton, Pennsylvania, the US.

Morphotek Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9

Morphotek Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morphotek Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Morphotek Enters into Research Agreement with Rockefeller University 11

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 12

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 13

Morphotek Enters into Agreement with Areva Med 14

Morphotek Enters into Agreement with Mayo Clinic 15

Morphotek Enters into Research Agreement with University of Wisconsin Madison 16

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 17

Stealth Biologics Enters into Co-Development Agreement with Morphotek 18

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 19

Licensing Agreements 20

Morphotek Enters into Licensing Agreement with Bliss Biopharma 20

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 21

Blaze Bioscience Enters into Licensing Agreement with Morphotek 22

Morphotek Inc-Key Competitors 23

Morphotek Inc-Key Employees 24

Morphotek Inc-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Product News 26

12/07/2017: Morphotek To Present Its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego 26

11/13/2017: Morphotek To Present Its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon 27

09/22/2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC 28

Clinical Trials 29

Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression 29

Sep 19, 2017: Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Morphotek Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Morphotek Inc, Pharmaceuticals & Healthcare, Key Facts 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9

Morphotek Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morphotek Enters into Research Agreement with Rockefeller University 11

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 12

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 13

Morphotek Enters into Agreement with Areva Med 14

Morphotek Enters into Agreement with Mayo Clinic 15

Morphotek Enters into Research Agreement with University of Wisconsin Madison 16

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 17

Stealth Biologics Enters into Co-Development Agreement with Morphotek 18

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 19

Morphotek Enters into Licensing Agreement with Bliss Biopharma 20

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 21

Blaze Bioscience Enters into Licensing Agreement with Morphotek 22

Morphotek Inc, Key Competitors 23

Morphotek Inc, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Morphotek Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Morphotek Inc (Morphotek), a subsidiary of Eisai Inc, is a clinical-stage biotechnology company that develops monoclonal antibodies, antibody drug conjugates, and bispecific antibodies to treat cancer, inflammatory and infectious diseases. Its pipeline product portfolio includes farletuzumab, a humanized IgG1 antibody targeting folate receptor alpha (FRA) for the treatment of ovarian and lung cancers; and amatuximab, a chimeric, IgG1 antibody that targets a cell-surface glycoprotein, mesothelin for treating mesothelioma. Morphotek also provides ontuxizumab targets cell-surface protein, endosialin for the treatment of cancers; gimsilumab against rheumatoid arthritis (RA); MORAb-202, an antibody drug conjugate (ADC) for metastatic breast cancer; and MORAb-048, MORAb-050 and MORAb-066 targeting tissue factor (TF) expressing malignancies. It offers services such as drug discovery and development, GLP and GMP production, antibodies investigation, antibody and protein engineering technologies, and others. The company works in partnership with other biotech companies, research organizations, and academic centers for discovery and development of its pipeline products. Morphotek is headquartered in Exton, Pennsylvania, the US.

Morphotek Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9

Morphotek Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morphotek Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Morphotek Enters into Research Agreement with Rockefeller University 11

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 12

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 13

Morphotek Enters into Agreement with Areva Med 14

Morphotek Enters into Agreement with Mayo Clinic 15

Morphotek Enters into Research Agreement with University of Wisconsin Madison 16

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 17

Stealth Biologics Enters into Co-Development Agreement with Morphotek 18

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 19

Licensing Agreements 20

Morphotek Enters into Licensing Agreement with Bliss Biopharma 20

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 21

Blaze Bioscience Enters into Licensing Agreement with Morphotek 22

Morphotek Inc-Key Competitors 23

Morphotek Inc-Key Employees 24

Morphotek Inc-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Product News 26

12/07/2017: Morphotek To Present Its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego 26

11/13/2017: Morphotek To Present Its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon 27

09/22/2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC 28

Clinical Trials 29

Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression 29

Sep 19, 2017: Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

Morphotek Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Morphotek Inc, Pharmaceuticals & Healthcare, Key Facts 2

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Morphotek Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Morphotek Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Morphotek Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Morphotek Inc, Medical Devices Deals, 2012 to YTD 2018 9

Morphotek Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Morphotek Enters into Research Agreement with Rockefeller University 11

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 12

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 13

Morphotek Enters into Agreement with Areva Med 14

Morphotek Enters into Agreement with Mayo Clinic 15

Morphotek Enters into Research Agreement with University of Wisconsin Madison 16

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 17

Stealth Biologics Enters into Co-Development Agreement with Morphotek 18

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 19

Morphotek Enters into Licensing Agreement with Bliss Biopharma 20

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 21

Blaze Bioscience Enters into Licensing Agreement with Morphotek 22

Morphotek Inc, Key Competitors 23

Morphotek Inc, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Morphotek Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.